Free Trial
NASDAQ:CELU

Celularity Q1 2026 Earnings Results & Report

Celularity logo
$0.61 -0.02 (-2.71%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Celularity reported Q1 2026 earnings on September 29, 2026. The company reported EPS of $0.02, while revenue was $3.85 million.

Earnings Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Celularity EPS Results

Actual EPS
$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 6 quarters

Celularity Revenue Results

Actual Revenue
$3.85 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Celularity Q1 2026 Earnings FAQ

Celularity (NASDAQ:CELU) reported earnings of $0.02 per share for Q1 2026. The report was announced on Tuesday, September 29, 2026.

Celularity reported revenue of $3.85 million for Q1 2026.

Celularity Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease.

The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. Its work focuses on developing and manufacturing placenta-derived products for clinical and commercial use.

View Celularity Profile